1. Home
  2. MRKR vs CXAI Comparison

MRKR vs CXAI Comparison

Compare MRKR & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • CXAI
  • Stock Information
  • Founded
  • MRKR N/A
  • CXAI N/A
  • Country
  • MRKR United States
  • CXAI United States
  • Employees
  • MRKR N/A
  • CXAI N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • CXAI EDP Services
  • Sector
  • MRKR Health Care
  • CXAI Technology
  • Exchange
  • MRKR Nasdaq
  • CXAI Nasdaq
  • Market Cap
  • MRKR 30.7M
  • CXAI 26.7M
  • IPO Year
  • MRKR N/A
  • CXAI N/A
  • Fundamental
  • Price
  • MRKR $3.47
  • CXAI $1.56
  • Analyst Decision
  • MRKR Strong Buy
  • CXAI
  • Analyst Count
  • MRKR 1
  • CXAI 0
  • Target Price
  • MRKR $19.00
  • CXAI N/A
  • AVG Volume (30 Days)
  • MRKR 91.1K
  • CXAI 2.0M
  • Earning Date
  • MRKR 11-14-2024
  • CXAI 11-12-2024
  • Dividend Yield
  • MRKR N/A
  • CXAI N/A
  • EPS Growth
  • MRKR N/A
  • CXAI N/A
  • EPS
  • MRKR N/A
  • CXAI N/A
  • Revenue
  • MRKR $5,395,849.00
  • CXAI $7,200,000.00
  • Revenue This Year
  • MRKR $35.94
  • CXAI $3.86
  • Revenue Next Year
  • MRKR N/A
  • CXAI $100.00
  • P/E Ratio
  • MRKR N/A
  • CXAI N/A
  • Revenue Growth
  • MRKR 79.04
  • CXAI N/A
  • 52 Week Low
  • MRKR $2.44
  • CXAI $1.03
  • 52 Week High
  • MRKR $6.16
  • CXAI $7.07
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 50.16
  • CXAI 46.97
  • Support Level
  • MRKR $3.47
  • CXAI $1.66
  • Resistance Level
  • MRKR $5.95
  • CXAI $1.96
  • Average True Range (ATR)
  • MRKR 0.63
  • CXAI 0.27
  • MACD
  • MRKR 0.01
  • CXAI -0.03
  • Stochastic Oscillator
  • MRKR 16.99
  • CXAI 12.50

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About CXAI CXApp Inc.

CXApp Inc is a workplace experience platform for enterprise customers. It is a SaaS product for enterprise organizations, distributing a mobile app to all employees within the organization. It includes a content management system (or CMS) so customers can adjust configurations for their workplace settings autonomously and spontaneously. Its technologies and solutions help enterprise customers deliver a comprehensive business journey in a work 'from anywhere' world for employees, partners, customers, and visitors. CXApp offers native mapping, analytics, on-device positioning (or ODP), and application technologies that bring people together.

Share on Social Networks: